Rapid Quantification of Glutamate Dehydrogenase and Toxin B (TcdB) with a NanoBiT Split-Luciferase Assay

Overview

Journal Anal Chem

Specialty Chemistry

Date 2022 May 31

PMID 35634999

Authors

Hope Adamson

Modupe O Ajayi

Kate E Gilroy

Michael J McPherson

Darren C Tomlinson

Lars J C Jeuken

Affiliations

Soon will be listed here.

Abstract

infection (CDI) is a leading healthcare-associated infection with a high morbidity and mortality and is a financial burden. No current standalone point-of-care test (POCT) is sufficient for the identification of true CDI over a disease-free carriage of , so one is urgently required to ensure timely, appropriate treatment. Here, two types of binding proteins, Affimers and nanobodies, targeting two biomarkers, glutamate dehydrogenase (GDH) and toxin B (TcdB), are combined in NanoBiT (NanoLuc Binary Technology) split-luciferase assays. The assays were optimized and their performance controlling parameters were examined. The 44 fM limit of detection (LoD), 4-5 log range and 1300-fold signal gain of the TcdB assay in buffer is the best observed for a NanoBiT assay to date. In the stool sample matrix, the GDH and TcdB assay sensitivity (LoD = 4.5 and 2 pM, respectively) and time to result (32 min) are similar to a current, commercial lateral flow POCT, but the NanoBit assay has no wash steps, detects clinically relevant TcdB over TcdA, and is quantitative. Development of the assay into a POCT may drive sensitivity further and offer an urgently needed ultrasensitive TcdB test for the rapid diagnosis of true CDI. The NanoBiTBiP (NanoBiT with Binding Proteins) system offers advantages over NanoBiT assays with antibodies as binding elements in terms of ease of production and assay performance. We expect this methodology and approach to be generally applicable to other biomarkers.

Citing Articles

An immunoassay based on bioluminescent sensors for rapid detection of African swine fever virus antibodies.

Zhang Z, Wang J, Niu Q, Guan G, Yin H, Yang J J Clin Microbiol. 2024; 62(10):e0046324.

PMID: 39235247 PMC: 11481549. DOI: 10.1128/jcm.00463-24.

Emerging Diagnostics in Infection.

Hulme J Int J Mol Sci. 2024; 25(16).

PMID: 39201359 PMC: 11354687. DOI: 10.3390/ijms25168672.

New treatment approaches for infections: alternatives to antibiotics and fecal microbiota transplantation.

Bratkovic T, Zahirovic A, Bizjak M, Rupnik M, Strukelj B, Berlec A Gut Microbes. 2024; 16(1):2337312.

PMID: 38591915 PMC: 11005816. DOI: 10.1080/19490976.2024.2337312.

Chimeric Protein Switch Biosensors.

Campbell E, Luxton T, Kohl D, Goodchild S, Walti C, Jeuken L Adv Biochem Eng Biotechnol. 2024; 187:1-35.

PMID: 38273207 DOI: 10.1007/10_2023_241.

Therapeutic drug monitoring of immunotherapies with novel Affimer-NanoBiT sensor construct.

Campbell E, Adamson H, Luxton T, Tiede C, Walti C, Tomlinson D Sens Diagn. 2024; 3(1):104-111.

PMID: 38249540 PMC: 10795742. DOI: 10.1039/d3sd00126a.

References

Fang Y, Chen S, Huang X, Wang L, Wang H, Wang J . Simple approach for ultrasensitive electrochemical immunoassay of Clostridium difficile toxin B detection. Biosens Bioelectron. 2013; 53:238-44. DOI: 10.1016/j.bios.2013.09.063. View

Yao Z, Drecun L, Aboualizadeh F, Kim S, Li Z, Wood H . A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies. Nat Commun. 2021; 12(1):1806. PMC: 7985487. DOI: 10.1038/s41467-021-22102-6. View

Brown K, Khanafer N, Daneman N, Fisman D . Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013; 57(5):2326-32. PMC: 3632900. DOI: 10.1128/AAC.02176-12. View

Quinn C, Sefers S, Babiker W, He Y, Alcabasa R, Stratton C . C. Diff Quik Chek complete enzyme immunoassay provides a reliable first-line method for detection of Clostridium difficile in stool specimens. J Clin Microbiol. 2009; 48(2):603-5. PMC: 2815622. DOI: 10.1128/JCM.01614-09. View

Crobach M, Planche T, Eckert C, Barbut F, Terveer E, Dekkers O . European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016; 22 Suppl 4:S63-81. DOI: 10.1016/j.cmi.2016.03.010. View

Han D, Oh J, Lee J, Cho Y, Park J, Choi J . Paper-based multiplex analytical device for simultaneous detection of Clostridioides difficile toxins and glutamate dehydrogenase. Biosens Bioelectron. 2020; 176:112894. DOI: 10.1016/j.bios.2020.112894. View

Hiblot J, Yu Q, Sabbadini M, Reymond L, Xue L, Schena A . Luciferases with Tunable Emission Wavelengths. Angew Chem Int Ed Engl. 2017; 56(46):14556-14560. DOI: 10.1002/anie.201708277. View

Ohmuro-Matsuyama Y, Ueda H . Homogeneous Noncompetitive Luminescent Immunodetection of Small Molecules by Ternary Protein Fragment Complementation. Anal Chem. 2018; 90(5):3001-3004. DOI: 10.1021/acs.analchem.7b05140. View

Ryder A, Huang Y, Li H, Zheng M, Wang X, Stratton C . Assessment of Clostridium difficile infections by quantitative detection of tcdB toxin by use of a real-time cell analysis system. J Clin Microbiol. 2010; 48(11):4129-34. PMC: 3020809. DOI: 10.1128/JCM.01104-10. View

10.

Hall M, Unch J, Binkowski B, Valley M, Butler B, Wood M . Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem Biol. 2012; 7(11):1848-57. PMC: 3501149. DOI: 10.1021/cb3002478. View

11.

Kim S, Dixon A, Adamovich P, Robinson P, Owen S . Homogeneous Immunoassay Using a Tri-Part Split-Luciferase for Rapid Quantification of Anti-TNF Therapeutic Antibodies. ACS Sens. 2021; 6(5):1807-1814. DOI: 10.1021/acssensors.0c02642. View

12.

Kainulainen M, Bergeron E, Chatterjee P, Chapman A, Lee J, Chida A . High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay. Sci Rep. 2021; 11(1):12330. PMC: 8192771. DOI: 10.1038/s41598-021-91300-5. View

13.

Sharp S, Ruden L, Pohl J, Hatcher P, Jayne L, Ivie W . Evaluation of the C.Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of clostridium difficile disease. J Clin Microbiol. 2010; 48(6):2082-6. PMC: 2884466. DOI: 10.1128/JCM.00129-10. View

14.

Armbruster D, Pry T . Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008; 29 Suppl 1:S49-52. PMC: 2556583. View

15.

Desai K, Gupta S, Dubberke E, Prabhu V, Browne C, Mast T . Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC Infect Dis. 2016; 16:303. PMC: 4912810. DOI: 10.1186/s12879-016-1610-3. View

16.

Carter G, Chakravorty A, Nguyen T, Mileto S, Schreiber F, Li L . Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections. mBio. 2015; 6(3):e00551. PMC: 4453007. DOI: 10.1128/mBio.00551-15. View

17.

Planche T, Wilcox M . Reference assays for Clostridium difficile infection: one or two gold standards?. J Clin Pathol. 2010; 64(1):1-5. DOI: 10.1136/jcp.2010.080135. View

18.

Drudy D, Fanning S, Kyne L . Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis. 2006; 11(1):5-10. DOI: 10.1016/j.ijid.2006.04.003. View

19.

Gite S, Archambault D, Cappillino M, Cunha D, Dorich V, Shatova T . A Rapid, Accurate, Single Molecule Counting Method Detects Clostridium difficile Toxin B in Stool Samples. Sci Rep. 2018; 8(1):8364. PMC: 5976643. DOI: 10.1038/s41598-018-26353-0. View

20.

Polage C, Gyorke C, Kennedy M, Leslie J, Chin D, Wang S . Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era. JAMA Intern Med. 2015; 175(11):1792-801. PMC: 4948649. DOI: 10.1001/jamainternmed.2015.4114. View